

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBLT-CELL CROSSMATCHING RESULTS OF SAMPLE 2A08/2014

DESPATCHED ON 15TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B7, B44; Cw7, Cw16; DR7 , -; DQ2 , -

Summary of Results					Summary of Results				
Total tested	20	20	19	20	16	16	16	16	
Positive	0	0	0	0	0	0	0	0	
Negative	20	20	19	20	16	16	16	16	
Not Tested	3	3	3	3	3	3	3	3	
% Positive	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
% Negative	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
<b>Consensus</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	
HLA Antibody (Defined By CDC)	A9,DR15	DR52	DQ1	Cw2					

  

Lab No.	Without DTT				With DTT ( Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Short staffed. Short staffed.
11	Negative	Negative	Equivocal	Negative	Negative	Negative	Negative	Negative	
12	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
14	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
15	NT	NT	NT	NT	NT	NT	NT	NT	
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
23	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
24	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
25	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
34	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
35	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
38	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
39	NT	NT	NT	NT	NT	NT	NT	NT	
41	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Results not reported sue to poor cell quality and granulocyte contamination
42	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
45	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
48	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
51	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
54	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
58	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
62	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

**PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 16TH SEPTEMBER 2014**

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A08/2014

DESPATCHED ON 15TH JULY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
9	0	0	0	0	0	0	0	0	16-Jul	17-Jul	Yes	Yes	90	Cedarlane	30	30	AO/PI	
11									16-Jul	17-Jul	Yes	Yes	95	Cedarlane	45	90	Fluoroquenched	
12	5%	5%	5%	5%	5%	5%	5%	5%	16-Jul	16-Jul	Yes	Yes	95	Cedarlane	30	90	EB/AO	
14	0	0	0	0	0	0	0	0	16-Jul	16-Jul	Yes	Yes	95	Cedarlane	60	120	EB/AO	
15	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
19	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
20	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	95	Cedarlane	30	60	EB/AO	
23	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	>90	Cedarlane	40	40	EB/AO	
24	20%	20%	20%	20%	20%	20%	10%	20%	16-Jul	17-Jul	Yes	Yes	80	Cedarlane	45	90	Fluoroquenched	
25	1	1	1	1	1	1	1	1	17-Jul	17-Jul	Yes	Yes	99	Cedarlane	45	60	Fluoroquenched	
28	1	1	1	1	1	1	1	1	16-Jul	17-Jul	Yes	Yes	95	Cedarlane	30	45	EB/AO	
34	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	99	Cedarlane	30	90	EB/AO	
35	1	1	1	1	1	1	1	1	16-Jul	17-Jul	Yes	Yes	80	Cedarlane	60	120	Fluoroquenched	
38	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	95	99	Cedarlane	60	60	EB/AO
39	NT	NT	NT	NT	NT	NT	NT	NT	16-Jul	16-Jul	Yes	No	90	Cedarlane	45	90	EB/AO	
41	0%	0%	0%	0%	0%	0%	0%	0%	16-Jul	16-Jul	Yes	No	95	Cedarlane	60	60	EB/AO	
42									16-Jul	16-Jul	Yes	No	95	TCS Biosciences	60	120	EB/AO	
45	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	99	Cedarlane	60	90	EB/AO	
48									16-Jul	16-Jul	Yes	No	90	Cedarlane	30	60	EB	
51	0	0	0	0	0	0	0	0	16-Jul	17-Jul	Yes	Yes	95	Cedarlane	60	60	Fluoroquenched	
54	0%	0%	0%	0%	0%	0%	0%	0%	16-Jul	17-Jul	Yes	Yes	>99	Cedarlane	60	60	PI	
58	5%	5%	5%	5%	5%	5%	5%	5%	16-Jul	16-Jul	Yes	Yes	95	Cedarlane	60	90	Fluoroquenched	
62	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	99	Cedarlane	60	120	EB/AO	

EB - ethidium bromide  
AO - acridine orange  
PI - propidium iodide  
Hb - haemoglobin  
CFDA - carboxy-fluorescein diacetate

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A08/2014

DESPATCHED ON 15TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B7, B44; Cw7, Cw16; DR7 ,;- ; DQ2 ,;-

Summary of Results					Summary of Results				
Total tested	19	19	19	19	16	15	16	16	16
Positive	1	11	7	2	0	3	5	0	0
Negative	18	8	12	17	16	12	11	16	16
Not Tested	2	2	2	2	2	3	2	2	2
% Positive	5.3%	57.9%	36.8%	10.5%	0.0%	20.0%	31.3%	0.0%	0.0%
% Negative	94.7%	42.1%	63.2%	89.5%	100.0%	80.0%	68.8%	100.0%	100.0%
<b>Consensus</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>
HLA Antibody (Defined By CDC)	A9,DR15	DR52	DQ1	Cw2					

Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Positive	Positive	Negative	Negative	NT	Positive	Negative	NT due to low cell count
11	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
12	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Short staffed. Short staffed.
14	Negative	Positive	Positive	Positive	Negative	Positive	Positive	Negative	
15	NT	NT	NT	NT	NT	NT	NT	NT	
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Negative	Positive	Positive	Negative	Negative	Negative	Negative	Negative	
23	Negative	Positive	Positive	Negative					
24	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
25	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
28	Negative	Weak Positive	Positive	Negative	Negative	Negative	Positive	Negative	
34	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
38	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
39	Negative	Positive	Positive	Positive	Negative	Negative	Positive	Negative	
41	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
42	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
45	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	
51	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
54	Positive	Positive	Negative	Negative					
58	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Results for serum 3 and 4 are equivocal due to poor performance of the local negative control serum
62	Negative	Positive	Negative	Negative					

**PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 16TH SEPTEMBER 2014**

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A08/2014

DESPATCHED ON 15TH JULY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
9	0	4	4	0	0	NT	4	0	16-Jul	17-Jul	Yes	90	Cedarlane	30	30	AO/PI
11									16-Jul	17-Jul	Yes	85	Cedarlane	45	90	Fluoroquench
12	10%	10%	10%	10%	10%	10%	10%	10%	16-Jul	16-Jul	Yes	90	Cedarlane	30	60	EB/AO
14	0	8	6	4	0	6	4	0	16-Jul	16-Jul	Yes	95	Cedarlane	60	120	EB/AO
15	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
19	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
20	1	3	3	1	1	1	1	1	16-Jul	16-Jul	Yes	95	Cedarlane	30	60	EB/AO
23	1	4	4	1					16-Jul	16-Jul	Yes	>90	Cedarlane	40	40	EB/AO
24	30%	30%	40%	40%	30%	30%	30%	30%	16-Jul	17-Jul	Yes	70	Cedarlane	45	90	Fluoroquench
25	1	4	1	1	1	4	1	1	17-Jul	17-Jul	Yes	99	Cedarlane	45	60	Fluoroquench
28	1	2-4	6-8	1-2	1	1	6	1	16-Jul	17-Jul	Yes	85	Cedarlane	30	45	EB/AO
34	1	4	2	1	1	2	2	1	16-Jul	16-Jul	Yes	97	Cedarlane	30	90	EB/AO
38	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	85	Cedarlane	60	60	EB/AO
39		8	6	4			2		16-Jul	16-Jul	Yes	95	Cedarlane	45	90	EB/AO
41	0%	0%	0%	0%	0%	0%	0%	0%	16-Jul	16-Jul	Yes	95	Cedarlane	45	45	EB/AO
42									16-Jul	16-Jul	Yes	90	TCS Biosciences	60	120	EB/AO
45	1	2-4	1	1	1	1	1	1	16-Jul	16-Jul	Yes	95	Cedarlane	30	75	EB/AO
51	0	0	0	0	0	0	0	0	16-Jul	17-Jul	Yes	95	Cedarlane	60	60	Fluoroquench
54	40%	60%	10%	10%					16-Jul	17-Jul	Yes	90	Cedarlane	60	60	PI
58	5%	5%	5%	5%	5%	5%	15%	15%	16-Jul	16-Jul	Yes	95	Cedarlane	60	90	Fluoroquench
62	1	8	1	1					16-Jul	16-Jul	Yes	75	Cedarlane	60	120	EB/AO
									16-Jul	16-Jul	Yes	70	Cedarlane	60	120	EB/AO

EB - ethidium bromide  
AO - acridine orange  
PI - propidium iodide  
Hb - haemoglobin  
CFDA - carboxy-fluorescein diacetate